Kiniksa Pharmaceuticals International (KNSA) Deferred Taxes (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Deferred Taxes for 10 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 51.12% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (up 114.97% YoY), and the FY2025 full-year result was $13.0 million, up 59.89% from the prior year.
• Deferred Taxes for Q1 2026 stood at $4.5 million, up from $3.1 million in the prior quarter.
• The five-year high for Deferred Taxes was $10.6 million in Q2 2024, with the low at -$25.7 million in Q4 2023.
• Historically, Deferred Taxes has averaged -$555928.6 across 5 years, with a median of $2.8 million in 2025.
• Annual changes were most pronounced in 2023 — Deferred Taxes plunged 7487.64% — and 2024, when it soared 305.29%.
• Kiniksa Pharmaceuticals International's Deferred Taxes stood at $348000.0 in 2022, then sank by 7487.64% to -$25.7 million in 2023, then jumped by 87.7% to -$3.2 million in 2024, then surged by 199.21% to $3.1 million in 2025, then jumped by 44.14% to $4.5 million in 2026.
• The last three Deferred Taxes figures came in at $4.5 million (Q1 2026), $3.1 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.